GlaxoSmithKline PLC’s first-in-class anti-BCMA antibody-drug conjugate – which now has breakthrough therapy designation in the US for relapsed and refractory multiple myeloma – "serves notice that GSK is truly back in the oncology business", its divisional R&D head said in an interview.
GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?